TY  - JOUR
AU  - Pires, Ana Salomé
AU  - Bollini, Sveva
AU  - Botelho, Maria Filomena
AU  - Lang-Olip, Ingrid
AU  - Ponsaerts, Peter
AU  - Balbi, Carolina
AU  - Lange-Consiglio, Anna
AU  - Fénelon, Mathilde
AU  - Mojsilović, Slavko
AU  - Berishvili, Ekaterine
AU  - Cremonesi, Fausto
AU  - Gazouli, Maria
AU  - Bugarski, Diana
AU  - Gellhaus, Alexandra
AU  - Kerdjoudj, Halima
AU  - Schoeberlein, Andreina
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1297
AB  - The last 18 years have brought an increasing interest in the therapeutic use of perinatal derivatives (PnD). Preclinical studies used to assess the potential of PnD therapy include a broad range of study designs. The COST SPRINT Action (CA17116) aims to provide systematic and comprehensive reviews of preclinical studies for the understanding of the therapeutic potential and mechanisms of PnD in diseases and injuries that benefit from PnD therapy. Here we describe the publication search and data mining, extraction, and synthesis strategies employed to collect and prepare the published data selected for meta-analyses and reviews of the efficacy of PnD therapies for different diseases and injuries. A coordinated effort was made to prepare the data suitable to make statements for the treatment efficacy of the different types of PnD, routes, time points, and frequencies of administration, and the dosage based on clinically relevant effects resulting in clear increase, recovery or amelioration of the specific tissue or organ function. According to recently proposed guidelines, the harmonization of the nomenclature of PnD types will allow for the assessment of the most efficient treatments in various disease models. Experts within the COST SPRINT Action (CA17116), together with external collaborators, are doing the meta-analyses and reviews using the data prepared with the strategies presented here in the relevant disease or research fields. Our final aim is to provide standards to assess the safety and clinical benefit of PnD and to minimize redundancy in the use of animal models following the 3R principles for animal experimentation.
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
T2  - Methods and Protocols
T1  - Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives
IS  - 3
SP  - 45
VL  - 6
DO  - 10.3390/mps6030045
ER  - 

@article{
author = "Pires, Ana Salomé and Bollini, Sveva and Botelho, Maria Filomena and Lang-Olip, Ingrid and Ponsaerts, Peter and Balbi, Carolina and Lange-Consiglio, Anna and Fénelon, Mathilde and Mojsilović, Slavko and Berishvili, Ekaterine and Cremonesi, Fausto and Gazouli, Maria and Bugarski, Diana and Gellhaus, Alexandra and Kerdjoudj, Halima and Schoeberlein, Andreina",
year = "2023",
abstract = "The last 18 years have brought an increasing interest in the therapeutic use of perinatal derivatives (PnD). Preclinical studies used to assess the potential of PnD therapy include a broad range of study designs. The COST SPRINT Action (CA17116) aims to provide systematic and comprehensive reviews of preclinical studies for the understanding of the therapeutic potential and mechanisms of PnD in diseases and injuries that benefit from PnD therapy. Here we describe the publication search and data mining, extraction, and synthesis strategies employed to collect and prepare the published data selected for meta-analyses and reviews of the efficacy of PnD therapies for different diseases and injuries. A coordinated effort was made to prepare the data suitable to make statements for the treatment efficacy of the different types of PnD, routes, time points, and frequencies of administration, and the dosage based on clinically relevant effects resulting in clear increase, recovery or amelioration of the specific tissue or organ function. According to recently proposed guidelines, the harmonization of the nomenclature of PnD types will allow for the assessment of the most efficient treatments in various disease models. Experts within the COST SPRINT Action (CA17116), together with external collaborators, are doing the meta-analyses and reviews using the data prepared with the strategies presented here in the relevant disease or research fields. Our final aim is to provide standards to assess the safety and clinical benefit of PnD and to minimize redundancy in the use of animal models following the 3R principles for animal experimentation.",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
journal = "Methods and Protocols",
title = "Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives",
number = "3",
pages = "45",
volume = "6",
doi = "10.3390/mps6030045"
}

Pires, A. S., Bollini, S., Botelho, M. F., Lang-Olip, I., Ponsaerts, P., Balbi, C., Lange-Consiglio, A., Fénelon, M., Mojsilović, S., Berishvili, E., Cremonesi, F., Gazouli, M., Bugarski, D., Gellhaus, A., Kerdjoudj, H.,& Schoeberlein, A.. (2023). Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives. in Methods and Protocols
Multidisciplinary Digital Publishing Institute (MDPI)., 6(3), 45.
https://doi.org/10.3390/mps6030045

Pires AS, Bollini S, Botelho MF, Lang-Olip I, Ponsaerts P, Balbi C, Lange-Consiglio A, Fénelon M, Mojsilović S, Berishvili E, Cremonesi F, Gazouli M, Bugarski D, Gellhaus A, Kerdjoudj H, Schoeberlein A. Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives. in Methods and Protocols. 2023;6(3):45.
doi:10.3390/mps6030045 .

Pires, Ana Salomé, Bollini, Sveva, Botelho, Maria Filomena, Lang-Olip, Ingrid, Ponsaerts, Peter, Balbi, Carolina, Lange-Consiglio, Anna, Fénelon, Mathilde, Mojsilović, Slavko, Berishvili, Ekaterine, Cremonesi, Fausto, Gazouli, Maria, Bugarski, Diana, Gellhaus, Alexandra, Kerdjoudj, Halima, Schoeberlein, Andreina, "Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives" in Methods and Protocols, 6, no. 3 (2023):45,
https://doi.org/10.3390/mps6030045 . .